Drug Type Small molecule drug |
Synonyms FAAH/MAGL Dual Inhibitor (BMS), ABD-115672, ABX-1772 + [4] |
Target |
Action inhibitors |
Mechanism FAAH inhibitors(Anandamide amidohydrolase inhibitors), MAGL inhibitors(Monoglyceride lipase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H21F3N4O4 |
InChIKeyXXDVCULQMDDOAX-CYBMUJFWSA-N |
CAS Registry2244136-58-9 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Agitation | Phase 2 | United States | 09 Jun 2025 | |
| Alzheimer Disease | Phase 2 | United States | 09 Jun 2025 | |
| Multiple Sclerosis | Phase 2 | United States | 05 Jun 2025 | |
| Multiple Sclerosis | Phase 2 | Australia | 05 Jun 2025 | |
| Multiple Sclerosis | Phase 2 | Canada | 05 Jun 2025 | |
| Multiple Sclerosis | Phase 2 | Czechia | 05 Jun 2025 | |
| Multiple Sclerosis | Phase 2 | Germany | 05 Jun 2025 | |
| Multiple Sclerosis | Phase 2 | Poland | 05 Jun 2025 | |
| Muscle Spasticity | Phase 2 | United States | 05 Jun 2025 | |
| Muscle Spasticity | Phase 2 | Australia | 05 Jun 2025 |





